✦ LIBER ✦

Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation

✍ Scribed by Kevin S. Choe; Daniel J. Haraf; Abhishek Solanki; Ezra E. W. Cohen; Tanguy Y. Seiwert; Kerstin M. Stenson; Elizabeth A. Blair; Louis Portugal; Victoria M. Villaflor; Mary Ellyn Witt; Everett E. Vokes; Joseph K. Salama

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 172 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26084

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toxicity and survival outcomes of hyperf

Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers

✍ John M. Watkins; Keisuke S. Shirai; Amy E. Wahlquist; Robert K. Stuart; Uzair B. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract ## __Background__. Reirradiation of locoregionally recurrent, previously irradiated head/neck cancer may be considered in situations of unresectability, medical inoperability, or adverse pathologic features found at salvage resection. ## __Methods__. Retrospective cohort analysis of

Toxicity and outcome analysis of patient

Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies

✍ Noel M. Kramer; Eric M. Horwitz; Jonathan Cheng; John A. Ridge; Steven J. Feigen 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

## Abstract ## Background. Patients with local recurrences or new head and neck primary tumors in previously irradiated tissues have few options for salvage treatment. One option for select patients is to undergo reirradiation with concurrent chemotherapy. The purpose of this study is to report th